down arrow

MediciNova, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US58468P2065
USD
1.55
0.08 (5.44%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.481.55

52 Week

1.132.37
Valuation
Technical
Day's Volume

CASH

103.78 k

Shareholding (Mar 2025)

FII

1.33%

Held by 15 FIIs

DII

93.2%

Held by 4 DIIs

Promoter

2.25%

How big is MediciNova, Inc.?

22-Jun-2025

As of Jun 18, MediciNova, Inc. has a market capitalization of 61.80 million and reported net sales of 0.00 million with a net profit of -11.15 million for the latest four quarters. Shareholder's funds are at 52.50 million and total assets at 55.88 million as of Dec 24.

As of Jun 18, MediciNova, Inc. has a market capitalization of 61.80 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -11.15 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 52.50 million and Total Assets at 55.88 million.

Read More

What does MediciNova, Inc. do?

22-Jun-2025

MediciNova, Inc. is a biopharmaceutical company developing small molecule therapeutics for serious diseases with unmet medical needs, classified as a micro-cap with a market cap of $61.80 million. As of March 2025, it reported a net profit loss of $3 million and has no dividend yield.

Overview: <BR>MediciNova, Inc. is a biopharmaceutical company focused on developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 61.80 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.73 <BR>Return on Equity: -22.35% <BR>Price to Book: 1.24<BR><BR>Contact Details: <BR>Address: 4275 Executive Sq Ste 300, LA JOLLA CA: 92037-8408 <BR>Tel: 1 858 3731500 <BR>Fax: 1 858 4040048 <BR>Website: https://medicinova.com/

Read More

Who are in the management team of MediciNova, Inc.?

22-Jun-2025

As of March 2022, the management team of MediciNova, Inc. includes Dr. Jeffrey Himawan (Independent Chairman), Dr. Yuichi Iwaki (President and CEO), Dr. Kazuko Matsuda (Chief Medical Officer), Ms. Carolyn Beaver (Director), and Mr. Hideki Nagao (Independent Director). They oversee the company's strategic direction and operations.

As of March 2022, the management team of MediciNova, Inc. includes the following individuals:<BR><BR>- Dr. Jeffrey Himawan, who serves as the Independent Chairman of the Board.<BR>- Dr. Yuichi Iwaki, who is the President, Chief Executive Officer, and Director.<BR>- Dr. Kazuko Matsuda, who holds the position of Chief Medical Officer and Director.<BR>- Ms. Carolyn Beaver, who is a Director.<BR>- Mr. Hideki Nagao, who is an Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is MediciNova, Inc. overvalued or undervalued?

25-Jun-2025

As of November 13, 2024, MediciNova, Inc. is considered overvalued and has deteriorated from a risky to a non-qualifying investment grade, with poor financial metrics and a year-to-date return of -37.62%, significantly underperforming compared to its industry peers and the S&P 500.

As of 13 November 2024, the valuation grade for MediciNova, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company is currently overvalued given its financial metrics, including a Price to Book Value of 1.39, an EV to EBIT of -2.57, and an ROCE of -94.04%. These figures suggest that the company is struggling to generate returns on its capital and is not in a favorable position relative to its peers.<BR><BR>In comparison to its industry peers, MediciNova's valuation metrics are concerning. For instance, Talaris Therapeutics, Inc. has a P/E ratio of -5.6255 and an EV to EBITDA of -2.2059, while Ocugen, Inc. shows a P/E of -5.5401 and an EV to EBITDA of -5.6869. These comparisons highlight that MediciNova is not only underperforming but also lacks a solid foundation for growth. Additionally, the company's stock has significantly lagged behind the S&P 500, with a year-to-date return of -37.62% compared to the index's 2.44%. Overall, MediciNova, Inc. appears to be overvalued in its current state.

Read More

Is MediciNova, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, MediciNova, Inc. is in a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -40.95% versus the index's 12.22%.

As of 12 September 2025, the technical trend for MediciNova, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on a weekly basis but bearish on a monthly basis, while the KST shows a similar pattern with mild bullishness weekly and bearishness monthly. The Bollinger Bands and moving averages indicate bearish trends, particularly on the daily timeframe. Dow Theory presents a mixed view, being mildly bearish weekly and mildly bullish monthly. <BR><BR>In terms of performance, MediciNova has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -40.95% versus the S&P 500's 12.22%, and a 1-year return of -20.00% compared to 17.14% for the index.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 62 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.73

stock-summary
Return on Equity

-25.21%

stock-summary
Price to Book

1.32

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
17.42%
0%
17.42%
6 Months
9.93%
0%
9.93%
1 Year
-32.61%
0%
-32.61%
2 Years
-12.92%
0%
-12.92%
3 Years
-40.15%
0%
-40.15%
4 Years
-50.48%
0%
-50.48%
5 Years
-74.17%
0%
-74.17%

MediciNova, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is MediciNova, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for MediciNova, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on a weekly basis but bearish on a monthly basis, while the KST shows a similar pattern with mild bullishness weekly and bearishness monthly. The Bollinger Bands and moving averages indicate bearish trends, particularly on the daily timeframe. Dow Theory presents a mixed view, being mildly bearish weekly and mildly bullish monthly. In terms of performance, MediciNova has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -40.95% versus the S&P 500's 12.22%, and a 1-year return of -20.00% compared to 17.14% for the index....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
2.47%
EBIT Growth (5y)
-1.68%
EBIT to Interest (avg)
-12.38
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.73
Sales to Capital Employed (avg)
0.01
Tax Ratio
0.05%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
11.71%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.39
EV to EBIT
-2.57
EV to EBITDA
-2.58
EV to Capital Employed
2.42
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-94.04%
ROE (Latest)
-22.35%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 7 Schemes (3.21%)

Foreign Institutions

Held by 15 Foreign Institutions (1.33%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -13.79% vs -3.57% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.60",
          "val2": "-3.20",
          "chgp": "-12.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.30",
          "val2": "-2.90",
          "chgp": "-13.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-26,798.80%",
          "val2": "0.00%",
          "chgp": "-2,679.88%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -27.91% vs 39.01% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "1.00",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.70",
          "val2": "-9.90",
          "chgp": "-28.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.00",
          "val2": "-8.60",
          "chgp": "-27.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-9,900.30%",
          "chgp": "990.03%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.10
0.00
Operating Profit (PBDIT) excl Other Income
-3.60
-3.20
-12.50%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.30
-2.90
-13.79%
Operating Profit Margin (Excl OI)
-26,798.80%
0.00%
-2,679.88%
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -13.79% vs -3.57% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
1.00
-100.00%
Operating Profit (PBDIT) excl Other Income
-12.70
-9.90
-28.28%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-11.00
-8.60
-27.91%
Operating Profit Margin (Excl OI)
0.00%
-9,900.30%
990.03%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -27.91% vs 39.01% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About MediciNova, Inc. stock-summary
stock-summary
MediciNova, Inc.
Pharmaceuticals & Biotechnology
Medicinova, Inc. is a biopharmaceutical company. The company is focused on developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs. The Company is developing activities on MN-166 (ibudilast) for neurological disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction (methamphetamine dependence, opioid dependence, and alcohol dependence), and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The Company’s pipeline includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.
Company Coordinates stock-summary
Company Details
4275 Executive Sq Ste 300 , LA JOLLA CA : 92037-8408
stock-summary
Tel: 1 858 3731500
stock-summary
https://medicinova.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."